Today: 28 February 2026
Subscribe
Browse Category

Health News 6 October 2025 - 1 January 2026

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics shares traded near $67.50 on Dec. 23, 2025, following strong Phase 2 data for its oral obesity drug aleniglipron, which showed up to 15.3% placebo-adjusted weight loss at 36 weeks. The company also closed a $747.5 million public offering after the trial results.
23 December 2025
····
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

The FDA approved Novo Nordisk’s once-daily Wegovy pill (oral semaglutide 25 mg) for chronic weight management and reducing cardiovascular risk in adults with obesity or overweight on December 22, 2025. The company plans a U.S. launch in January 2026 at $149 per month for eligible patients. Clinical trials showed average weight loss of 13.6% to 16.6% depending on adherence.
23 December 2025
··
So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

Danone U.S. has recalled So Delicious Dairy Free Salted Caramel Cluster pints nationwide after small stones and other hard objects were found in cashew pieces, according to the FDA. The recall covers pints with UPC 744473476138 and best-by dates before Aug. 8, 2027. Major retailers, including Target, Whole Foods, and Walmart in Hawai‘i, have been affected. Other So Delicious flavors are not included.
18 December 2025
·
California Vega Farms Egg Recall: 63 Sick, 13 Hospitalized in Salmonella Outbreak—How to Identify Affected Eggs

California Vega Farms Egg Recall: 63 Sick, 13 Hospitalized in Salmonella Outbreak—How to Identify Affected Eggs

California health officials have linked 63 Salmonella illnesses and 13 hospitalizations to Vega Farms in-shell brown eggs, prompting a recall on Dec. 5. The eggs were sold in Sacramento and Davis through retail stores, restaurants, and farmers markets. Testing found Salmonella matching the outbreak strain in samples from Vega Farms. No deaths have been reported.
16 December 2025
McCain Pizza Pockets Recall Australia 2025: Cheese & Bacon 400g Pulled from Woolworths, Coles and IGA After Plastic and Metal Contamination Warning

McCain Pizza Pockets Recall Australia 2025: Cheese & Bacon 400g Pulled from Woolworths, Coles and IGA After Plastic and Metal Contamination Warning

McCain Foods has recalled McCain Cheese & Bacon Pizza Pockets 400g nationwide after reports of plastic found inside the product, with possible metal contamination also not ruled out. The recall affects batch code 1005481714 with best-before dates OCT 2026 A (289–291), sold at major supermarkets and online across Australia. Food authorities warn consumers not to eat the product and to return it for a refund.
12 December 2025
···
Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson shares closed at $199.96 on December 9, down 0.8% after touching $205.54 intraday. After the bell, the company reported Phase 3 data showing its TECVAYLI® + DARZALEX FASPRO® combination cut multiple myeloma progression or death risk by 83%. JNJ paid a $1.30 quarterly dividend, marking 63 years of dividend growth. Analyst consensus sees modest upside, with targets near $203–207.
10 December 2025
···
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna shares jumped nearly 9% on December 5, closing at about $27–28 after a large French study backed the long-term safety and effectiveness of mRNA COVID vaccines. The stock remains down roughly 34% year-to-date and trades around 40% below its 52-week high. Investors also weighed a new $1.5 billion loan deal and updated guidance on future growth.
5 December 2025
··
Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

Costco has recalled its prepared Caesar Salad (item #19927) and Chicken Sandwich with Caesar Salad (item #11444) after plastic fragments were found in dressing packets supplied by Ventura Foods. The recall covers products sold in select Midwest, Northeast, and Southeast warehouses with sell-by dates from October 17 to November 9, 2025. Members are urged to check refrigerators for leftover dressing packets.
25 November 2025
·
Yoplait YOP Drinkable Yogurt Recall in Canada: Full List of Affected Products, Best-Before Dates and What Shoppers Should Do – November 24, 2025

Yoplait YOP Drinkable Yogurt Recall in Canada: Full List of Affected Products, Best-Before Dates and What Shoppers Should Do – November 24, 2025

The Canadian Food Inspection Agency has recalled all flavours of Yoplait YOP 200 mL drinkable yogurt nationwide due to possible plastic contamination. The recall, issued November 22, is classified as Class 1, CFIA’s highest risk level. No injuries or illnesses have been reported. The recall covers single bottles and multi-packs with best-before dates up to January 1.
24 November 2025
·
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia said a patient in its Phase 3 MAGNITUDE trial died after severe liver toxicity; FDA clinical holds on MAGNITUDE and MAGNITUDE-2 remain. NTLA shares fell as RBC cut its price target to $9, citing increased risk. The company reported $669.9 million in cash and securities, expecting its runway to last into mid-2027. Work continues on its hereditary angioedema program.
7 November 2025
···
Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

The FDA on Oct. 14 classified the recall of millions of eggs from Arkansas’ Black Sheep Egg Co. and Texas’ Kenz Henz as Class I, the highest severity, after inspectors found salmonella in 40 samples at Black Sheep’s plant. No illnesses have been reported. The recall affects Black Sheep and Kenz Henz eggs distributed in several states. Consumers are urged not to eat or sell the recalled eggs and to sanitize surfaces.
22 October 2025
·
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL shares surged 14% to a record $85.35 on Oct. 16 after Samsung agreed to invest $110 million and partner on cancer test rollout in Asia. New trial data showed Galleri’s blood test boosted early cancer detection seven-fold in a 25,000-patient study. GRAIL secured $325 million in fresh funding, extending its cash runway into 2030. Analysts remain cautious, with a consensus Hold rating and a $57 price target.
20 October 2025
···
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences shares jumped over 20% in pre-market trading Friday after receiving an FDA Commissioner’s National Priority Voucher for its lead drug, cytisinicline. The FDA also accepted Achieve’s New Drug Application for cytisinicline as a smoking cessation treatment, with a decision expected by June 2026. ACHV stock reached multi-month highs near $3 following the news. The company’s market cap is about $160 million.
17 October 2025
··
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility shares surged 89.6% to $1.43 on Oct. 16, with intraday highs of $2.03 and over 108 million shares traded—far above its 5.5 million share float. The rally follows a $200,000 preferred share sale and a recent SEC filing to register 8.35 million shares for resale. The company remains unprofitable and faces liquidity pressures. Year-to-date, the stock is up 95% but still trades 98% below its 52-week high.
16 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
15 October 2025
···
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences shares jumped over 250% intraday on Oct. 6, 2025, after the FDA granted Breakthrough Therapy Designation to its lead drug, tralesinidase alfa, for Sanfilippo Syndrome Type B. The stock rose from around $9 to $31. Spruce regained its Nasdaq listing in September following a reverse split. The company reported $16.4 million in cash as of June 30 and remains unprofitable.
6 October 2025
··
1 2 3
Go toTop